Literature DB >> 2455448

Interferons and autoimmunity.

A Schattner1.   

Abstract

Autoimmunity can be accelerated in several genetically prone murine models and can even be induced in normal mice by treatment with interferon (IFN) or IFN-inducers. Several cases of IFN-induced autoimmune disease in humans also have been observed; however, more striking is the fact that some of the clinical manifestations in autoimmune diseases and many of the immunological aberrations can be mediated or enhanced by IFN. The finding of high levels of circulating IFN in many patients may be highly significant in that respect, and the characterization of the predominant type of IFN as an unusual acid-labile IFN-alpha may indicate an infectious etiologic agent in autoimmunity, since this peculiar IFN was mostly associated with viral infections in vivo or in vitro. The induction of MHC class II antigens on previously HLA-DR or Ia negative cells appears to be caused primarily by IFN-gamma and may have a central role in the pathogenesis of autoimmunity in susceptible individuals. Such aberrant HLA-DR expression on nonlymphoid cells can be detected early in the disease in the target organs of many varied autoimmune conditions and may trigger a cascade of self-directed, uncontrolled immune response in conjunction with other factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455448     DOI: 10.1097/00000441-198806000-00007

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.

Authors:  J Cianciara; T Laskus
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

2.  Tumour necrosis factor production and cell-mediated immunity in anorexia nervosa.

Authors:  A Schattner; M Steinbock; R Tepper; A Schonfeld; N Vaisman; T Hahn
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

3.  Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C.

Authors:  H Unoki; A Moriyama; A Tabaru; A Masumoto; M Otsuki
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 4.  Drug-induced "allergic hepatitis".

Authors:  P Podevin; M Biour
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-{alpha}2a and ribavirin: a case report and literature review.

Authors:  Albéric-Rembrandt Gayet; Patrick Plaisance; Jean-François Bergmann; Stéphane Mouly
Journal:  Clin Med Res       Date:  2010-09-17

Review 6.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 8.  Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.

Authors:  T Maeda; S Onishi; T Miura; S Iwamura; A Tomita; T Saibara; Y Yamamoto
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

9.  Multisystem Sarcoidosis in a Patient on Interferon-α Therapy for Chronic Hepatitis C.

Authors:  Bouchra Oudghiri; Mohammed Benzagmout; Saïd Boujraf; Fawzi Belahcen; Adil Ibrahimi
Journal:  J Glob Infect Dis       Date:  2012-04

10.  Sterile Corneal Ulcer and Sjögren's Syndrome Associated with Long-Term Interferon alpha-2b Treatment in a Case of Multiple Myeloma.

Authors:  Yin-Tsu Liu; Ko-Hua Chen; Wen-Ming Hsu
Journal:  Int J Biomed Sci       Date:  2006-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.